We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 23

Australian case notes - Odisho v Bonazzi 2014 VSCA 11

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • May 20 2014

In this case the appellant, a patient who suffered a thromboembolic event following the use of tranexamic acid, claimed that her doctor had

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

It's a fact ... in my opinion

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • May 5 2011

What happens when the court is asked to pass judgement on that which cannot be proved?

Federal Court prescribes hard medicine for Vioxx class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 15 2012

The full court of the Federal Court of Australia recently overturned a damages award in the VIOXX class action, confirming once again that issues of causation are no less difficult to prove in large-scale class actions than in individual proceedings

Just genes? Lessons from the Myriad litigation

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are

Competition regulators continue their campaign against pharmaceutical companies

  • King & Wood Mallesons
  • -
  • Australia, USA
  • -
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

Pharmaceuticals - copyright in PIs and indirect patent infringement

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 4 2011

In the recent decision in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3), Justice Jagot of the Federal Court found liability for indirect patent infringement in the context of supply of a pharmaceutical product

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

It's all in the definition - "drug" or "pharmaceutical item"

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • May 19 2011

AstraZeneca has been unsuccessful in its attempt to overturn a decision of the Minister for Health and Ageing to include a particular dose of rosuvastatin (sold as Crestor, to lower cholesterol) in the Statins-HP "therapeutic group" on the Pharmaceutical Benefits Scheme ("PBS"

European Court of Justice says no to patents requiring the destruction of a human embryo - an Australian perspective

  • King & Wood Mallesons
  • -
  • Australia, European Union
  • -
  • October 20 2011

Article 6(2)(c) of the European Biotech Directive excludes inventions which use human embryos for industrial or commercial purposes from patentability